PA8490601A1 - Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos. - Google Patents

Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos.

Info

Publication number
PA8490601A1
PA8490601A1 PA20008490601A PA8490601A PA8490601A1 PA 8490601 A1 PA8490601 A1 PA 8490601A1 PA 20008490601 A PA20008490601 A PA 20008490601A PA 8490601 A PA8490601 A PA 8490601A PA 8490601 A1 PA8490601 A1 PA 8490601A1
Authority
PA
Panama
Prior art keywords
useful
anticancerigen
heteroarilo
quinolin
agents
Prior art date
Application number
PA20008490601A
Other languages
English (en)
Spanish (es)
Inventor
Bingwei Vera Yang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8490601A1 publication Critical patent/PA8490601A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PA20008490601A 1999-02-11 2000-02-10 Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos. PA8490601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11970299P 1999-02-11 1999-02-11

Publications (1)

Publication Number Publication Date
PA8490601A1 true PA8490601A1 (es) 2002-07-30

Family

ID=22385869

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20008490601A PA8490601A1 (es) 1999-02-11 2000-02-10 Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos.

Country Status (39)

Country Link
US (3) US6258824B1 (2)
EP (1) EP1150973B1 (2)
JP (3) JP4090200B2 (2)
KR (1) KR20010102073A (2)
CN (1) CN1340051A (2)
AP (1) AP2001002241A0 (2)
AR (1) AR028985A1 (2)
AT (1) ATE297916T1 (2)
AU (1) AU2124800A (2)
BG (1) BG105860A (2)
BR (1) BR0008202A (2)
CA (1) CA2362394C (2)
CO (1) CO5140097A1 (2)
CZ (1) CZ20012910A3 (2)
DE (1) DE60020812T2 (2)
DZ (1) DZ3009A1 (2)
EA (1) EA200100766A1 (2)
EE (1) EE200100425A (2)
ES (1) ES2243228T3 (2)
GT (1) GT200000014A (2)
HK (1) HK1042096A1 (2)
HN (1) HN2000000019A (2)
HR (1) HRP20010574A2 (2)
HU (1) HUP0105231A3 (2)
ID (1) ID29584A (2)
IL (1) IL144307A0 (2)
IS (1) IS5997A (2)
MA (1) MA26718A1 (2)
NO (1) NO20013909L (2)
OA (1) OA11833A (2)
PA (1) PA8490601A1 (2)
PE (1) PE20001464A1 (2)
PL (1) PL349839A1 (2)
SK (1) SK11002001A3 (2)
SV (1) SV2001000020A (2)
TN (1) TNSN00028A1 (2)
TR (2) TR200201297T2 (2)
WO (1) WO2000047574A1 (2)
ZA (1) ZA200106520B (2)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID26987A (id) * 1998-07-06 2001-02-22 Janssen Pharmaceutica Nv Inhibitor-inhibitor transferase protein farnesil dengan sifat-sifat peka terhadap sinar radiasi in vivo
PL349839A1 (en) * 1999-02-11 2002-09-23 Pfizer Prod Inc Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
ATE260269T1 (de) 1999-11-05 2004-03-15 Cytovia Inc Substituierte 4h-chromene und ähnliche verbindungen als kaspasis aktivatoren und apoptosis induktoren und deren verwendung
PT1106612E (pt) * 1999-11-30 2004-06-30 Pfizer Prod Inc Derivados de quinolina uteis para inibir a farnesil-proteina-transferase
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
AU3653301A (en) * 2000-01-28 2001-08-07 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
JO2361B1 (en) * 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
EP1170011A1 (en) * 2000-07-06 2002-01-09 Boehringer Ingelheim International GmbH Novel use of inhibitors of the epidermal growth factor receptor
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
WO2002024682A1 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
WO2002024686A2 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
US7173040B2 (en) 2000-09-25 2007-02-06 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
CZ20031145A3 (cs) * 2000-10-02 2003-12-17 Janssen Pharmaceutica N.V. Antagonisté metabotropního glutamátového receptoru
JP4348080B2 (ja) 2000-11-21 2009-10-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害するベンゾ複素環誘導体
JP4351444B2 (ja) * 2000-12-27 2009-10-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する４−ヘテロシクリル−キノリンおよびキナゾリン誘導体
ES2260316T3 (es) 2000-12-27 2006-11-01 Janssen Pharmaceutica N.V. Derivados de quinazolina y quinolina 4-sustituidos que inhiben la farnesil transferasa.
WO2002092594A1 (en) * 2001-05-16 2002-11-21 Cytovia, Inc. Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2002092076A1 (en) * 2001-05-16 2002-11-21 Cytovia, Inc. Substituted coumarins and quinolines as caspases activators
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2003006006A1 (en) * 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
ATE425978T1 (de) 2001-12-19 2009-04-15 Janssen Pharmaceutica Nv Durch c-verbundene imidazole substituierte 1,8- annellierten chinolon-derivate als farnesyl transferase inhibitoren
JP4450628B2 (ja) * 2002-03-22 2010-04-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼインヒビターとして使用するためのベンジルイミダゾリル置換２−キノリンおよびキナゾリン誘導体
CA2479109C (en) * 2002-03-29 2011-08-02 Janssen Pharmaceutica N.V. Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
EP1513515A2 (en) 2002-05-16 2005-03-16 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
CN100349887C (zh) 2002-05-16 2007-11-21 西托维亚公司 取代的4－芳基－4h－吡咯并[2,3－h]色烯和类似物及其药物组合物和用途
US20040186160A1 (en) * 2002-12-13 2004-09-23 Sugen, Inc. Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
WO2004056806A1 (en) * 2002-12-19 2004-07-08 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
DK1603570T5 (da) 2003-02-26 2013-12-09 Sugen Inc Aminoheteroarylforbindelser som proteinkinaseinhibitorer
WO2004076446A1 (ja) * 2003-02-27 2004-09-10 Chugai Seiyaku Kabushiki Kaisha ベンゾチオフェン誘導体
EP1660087A2 (en) * 2003-07-22 2006-05-31 Janssen Pharmaceutica N.V. Quinolinone derivatives as inhibitors of c-fms kinase
JP4691041B2 (ja) 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Ｇｔｐアーゼ阻害剤および使用方法
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
JP2007529555A (ja) * 2004-03-18 2007-10-25 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
CA2559285A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
EP1786777A1 (en) * 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
DE602005020465D1 (de) 2004-08-26 2010-05-20 Pfizer Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
ES2355923T3 (es) * 2004-08-26 2011-04-01 Pfizer, Inc. Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
EP1807426A2 (en) * 2004-10-07 2007-07-18 Cytovia, Inc. SUBSTITUTED N-ARYL-1H-PYRAZOLOÝ3,4-b¨QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS
US7826982B2 (en) 2005-07-29 2010-11-02 Children's Hospital Medical Center Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE
NZ566774A (en) 2005-09-07 2011-11-25 Pfizer Human monoclonal antibodies to activin receptor-like kinase-1
CA2623125A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2634598A1 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
EP2258700A1 (en) 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
CL2007002404A1 (es) 2006-08-21 2008-04-18 Hoffmann La Roche Uso de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular) para el tratamiento de un paciente que padece una recaida de cancer her2 positivo durante o despues del tratamiento con un anticuerpo anti-her2.
BRPI0812385A2 (pt) * 2007-05-23 2019-09-24 Allergan Inc lactamas cíclicas para o tratamento de glaucoma ou pressão intraocular elevada
CA2687973C (en) * 2007-05-23 2015-04-07 Allergan, Inc. ((bicylicheteroaryl) imidazolyl)methylheteroaryl compounds as adrenergic receptor agonists
US8129356B2 (en) * 2007-10-01 2012-03-06 Vanderbilt University Bmx mediated signal transduction in irradiated vascular endothelium
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
NZ593090A (en) * 2008-11-13 2013-06-28 Link Medicine Corp Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
TW201041892A (en) 2009-02-09 2010-12-01 Supergen Inc Pyrrolopyrimidinyl Axl kinase inhibitors
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2011109572A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP3812387A1 (en) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
CN104884448A (zh) 2012-10-16 2015-09-02 詹森药业有限公司 Rorγt的杂芳基连接的喹啉基调节剂
CN105073729A (zh) 2012-10-16 2015-11-18 詹森药业有限公司 RORγt的苯基连接的喹啉基调节剂
US9290476B2 (en) 2012-10-16 2016-03-22 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
MX394360B (es) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
BR112016008258A2 (pt) 2013-10-15 2017-10-10 Janssen Pharmaceutica Nv moduladores de ror?t de quinolinila
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
WO2017096165A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
CN108003150A (zh) * 2016-10-31 2018-05-08 河南工业大学 4-杂芳基喹啉酮衍生物的制备方法及其应用
AU2019310590A1 (en) 2018-07-26 2021-01-14 Sumitomo Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
KR20260008165A (ko) 2019-02-12 2026-01-15 스미토모 파마 아메리카, 인크. 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
CN114450027A (zh) 2019-08-16 2022-05-06 儿童医院医疗中心 用cdc42特异性抑制剂治疗受试者的方法
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2732531A1 (de) * 1977-07-19 1979-02-01 Hoechst Ag Imidazolcarbonsaeuren und deren derivate
US4835154A (en) * 1987-06-01 1989-05-30 Smithkline Beckman Corporation 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors
US5053543A (en) * 1990-11-28 1991-10-01 Glaxo Inc. Synthesis of 2-aminobenzophenones
US5136085A (en) * 1990-11-28 1992-08-04 Glaxo Inc. Synthesis of 2-aminobenzophenones
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
SK283335B6 (sk) * 1995-12-08 2003-06-03 Janssen Pharmaceutica N. V. (Imidazol-5-yl)metyl-2-chinolinónové deriváty, spôsob a medziprodukty na ich prípravu, ich použitie a farmaceutické kompozície na ich báze
AU740603B2 (en) * 1997-06-02 2001-11-08 Janssen Pharmaceutica N.V. (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
ID27562A (id) 1998-08-27 2001-04-12 Pfizer Prod Inc Turunan-turunan kinolin-2-ona tersubstitusi alkunil yang berguna sebagai zat anti kanker
PL349839A1 (en) * 1999-02-11 2002-09-23 Pfizer Prod Inc Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents

Also Published As

Publication number Publication date
WO2000047574A1 (en) 2000-08-17
EP1150973A1 (en) 2001-11-07
HN2000000019A (es) 2001-07-30
HUP0105231A2 (hu) 2002-04-29
CO5140097A1 (es) 2002-03-22
ATE297916T1 (de) 2005-07-15
CZ20012910A3 (cs) 2002-02-13
BR0008202A (pt) 2002-02-19
TR200201296T2 (tr) 2002-07-22
TR200201297T2 (tr) 2002-06-21
IL144307A0 (en) 2002-05-23
EE200100425A (et) 2002-12-16
MA26718A1 (fr) 2004-12-20
JP2002536444A (ja) 2002-10-29
PL349839A1 (en) 2002-09-23
KR20010102073A (ko) 2001-11-15
DZ3009A1 (fr) 2004-03-27
NO20013909L (no) 2001-10-08
CA2362394C (en) 2006-01-17
PE20001464A1 (es) 2000-12-20
SK11002001A3 (sk) 2002-05-09
CN1340051A (zh) 2002-03-13
EA200100766A1 (ru) 2002-02-28
CA2362394A1 (en) 2000-08-17
AP2001002241A0 (en) 2001-09-30
AU2124800A (en) 2000-08-29
ZA200106520B (en) 2002-08-26
NO20013909D0 (no) 2001-08-10
BG105860A (en) 2002-03-29
ES2243228T3 (es) 2005-12-01
ID29584A (id) 2001-09-06
JP4216740B2 (ja) 2009-01-28
JP4090200B2 (ja) 2008-05-28
EP1150973B1 (en) 2005-06-15
US20020120145A1 (en) 2002-08-29
OA11833A (en) 2005-08-23
HK1042096A1 (zh) 2002-08-02
GT200000014A (es) 2001-08-03
HUP0105231A3 (en) 2003-01-28
DE60020812T2 (de) 2006-05-04
US6258824B1 (en) 2001-07-10
TNSN00028A1 (fr) 2005-11-10
DE60020812D1 (de) 2005-07-21
US6710209B2 (en) 2004-03-23
IS5997A (is) 2001-07-10
HRP20010574A2 (en) 2002-12-31
US6388092B2 (en) 2002-05-14
AR028985A1 (es) 2003-06-04
JP2005002124A (ja) 2005-01-06
US20020019530A1 (en) 2002-02-14
SV2001000020A (es) 2001-11-08
JP2004182741A (ja) 2004-07-02

Similar Documents

Publication Publication Date Title
PA8490601A1 (es) Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos.
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
AR018705A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos.
PA8480101A1 (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos
CU23132A3 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
PA8494101A1 (es) Derivados heterociclicos utiles como agentes anticancerosos
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
UY26872A1 (es) Derivados de la 4- fenil piridina
UY27322A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
AR020032A1 (es) Derivados de 1,3 -metil eritromicina.
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
SV2004001419A (es) Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal" ref.pc23005
PA8474401A1 (es) 3-ceto derivados triciclicos de 6-0-metileritromicina
ECSP003347A (es) Derivados quinolin - 2- ona sustituidos con heteroarilo utiles como agentes anticancerigenos
ECSP993117A (es) Derivados de quinolin -2 - ona utiles como agentes contra el cancer
UY26785A1 (es) Derivados bicíclicos sustituidos para el tratamiento del crecimiento celular anormal
TR200102315T2 (tr) Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2- on türevleri.
UY28131A1 (es) Derivados biciclicos para el tratamiento del crecimiento celular anormal
DOP2003000786A (es) Derivados biciclicos para el tratamiento del crecimiento celular anormal.
ECSP972047A (es) Nuevos derivados de arilglicinamida, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos
UY27557A1 (es) Procedimiento para la preparación de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
ECSP993118A (es) Derivados de quinolin -2 -ona alquinilsustituidos utiles como agentes anticancerosos